Baricitinib 4 MG Oral Tablet
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Frontal Fibrosing Alopecia
Conditions
Frontal Fibrosing Alopecia
Trial Timeline
Apr 22, 2024 → Jul 31, 2027
NCT ID
NCT06240351About Baricitinib 4 MG Oral Tablet
Baricitinib 4 MG Oral Tablet is a approved stage product being developed by Eli Lilly for Frontal Fibrosing Alopecia. The current trial status is active. This product is registered under clinical trial identifier NCT06240351. Target conditions include Frontal Fibrosing Alopecia.
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06240351 | Approved | Active |
Competing Products
1 competing product in Frontal Fibrosing Alopecia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| POST Triheptanoin | Ultragenyx Pharmaceutical | Phase 1/2 | 26 |